← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tezcat Laboratories Llc
New Haven, CT
$4,317,521
Total funding
4
Grants
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,317,521 · 4
By mechanism
R44$3,308,943 · 2
R41$1,008,578 · 2
Investigators at Tezcat Laboratories Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$1,113,257
R44 · FY2025 · CA
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$1,062,082
R44 · FY2023 · CA
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$928,011
R44 · FY2024 · CA
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$399,877
R41 · FY2020 · CA
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$398,715
R41 · FY2021 · CA
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$209,986
R41 · FY2022 · CA
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$205,593
R44 · FY2025 · CA